Geron (GERN) Announces Data From The Imbark Phase 2 Clinical Trial In Annals Of Hematology

Geron Corporation in the pre-market increased by 4.48% and amounted to $1.4000. This month, the dynamics of stock prices are not stable. On October 5, the stock price increased to $1.3900. The next day it fell to $1.3150. On October 7, the price jumped to $1.3700. And yesterday, GERN stock closed at $1.3400, 1.52% above the starting point. Geron Corporation (GERN), today announced the publication in the Annals of Hematology.

The article, called “Favorable overall survival with Imetelstat in patients with recurrent/refractory myelofibrosis compared to real-world data”, describes statistical analyses in which data from the Company’s Phase 2 Imbark clinical trial are compared with data close to Real World Data (RWD). This article also describes in detail the methods of statistical adjustment and sensitivity analysis to improve the comparability of the data set that was obtained in the research and the 2nd phase of the Company’s IMbark and RWD. The researchers explain the stability in risk ratios and statistical significance observed across many studies, indicating that treating patients with MF with imetelstat following ruxolitinib failure has a survival benefit.